Leading the way in innovation for over 55 years, we build greater futures for businesses across multiple industries and 55 countries.
Our expert, committed team put our shared beliefs into action – every day. Together, we combine innovation and collective knowledge to create the extraordinary.
We share news, insights, analysis and research – tailored to your unique interests – to help you deepen your knowledge and impact.
At TCS, we believe exceptional work begins with hiring, celebrating and nurturing the best people — from all walks of life.
Get access to a catalog of the latest news stories from across TCS. Discover our press releases, reports, and company announcements.
Dr Srinivasan Jayaraman
Principal scientist, TCS
You have these already downloaded
We have sent you a copy of the report to your email again.
Investigating drug interaction, under hypoxia conditions with and without pro-arrhythmic comorbidity.
A transmural anisotropic ventricular tissue model consists of endocardial, mid-myocardial, and epicardial myocytes which are configured to investigate drug interaction, such as Hydroxychloroquine (HCQ), under hypoxia conditions without and with pro-arrhythmic comorbidity. In the ventricular model, HCQ has a trivial effect on hypoxia, except in the combination of mild hypoxia with moderate hypokalemia and severe hypoxia with mild hypokalemia, where it initiates reentrant arrhythmia. Secondly, incorporating drug dosage variations indicates 10 μM HCQ for all settings except in severe hypoxia conditions where reentrant arrhythmia occurred.
The protocol influences the appearance of reentrant arrhythmia for severe hypoxia with 10 μM HCQ dosage. For other conditions, including tachycardiac pacing protocol, no arrhythmia occurred. These findings infer that the arrhythmic fatality rate can be alleviated by altering the dosage of HCQ and can aid in the treatment of hypoxia-induced symptoms caused by COVID-19.
The author would like to thank Dr Ponnuraj Kirthi Priya for her outstanding contribution to this research-led article. Dr. Kirthi was a Scientist at DMMT, TCS, and had completed her Ph.D. from IIT Madras.
TCS Life Sciences Forum: Unlocking the Power of AI and Generative AI
EU MDR deadline extension: Making medtech manufacturers future-ready
Integrating Safety and Regulatory Functions -- A Bold Step in Pharma
Overcoming Regulatory Challenges in Personalized Medicine
Integrated ecosystems are key to better patient outcomes.
Talk to our experts